News & Statements
T1International’s 2022 Out-of-Pocket Cost Survey: An Easy Way to Advocate
27 May 2022, 9:32 p.m. in #insulin4all USA, News & Statements by T1International
Take the Survey! The survey is for individuals over the age of 18 with type 1 diabetes. A parent or caregiver can take the survey for those under the age of 18. Caregivers can also take the survey for spouses or partners. The survey is anonymous and is completely optional. Read more
Global Advocacy Success Series: Lejla Druškić, Bosnia and Herzegovina
2 May 2022, 6:48 p.m. in Global Stories, Interviews, News & Statements by Katie Souris
Lejla Druškić, Global Advocate from Bosnia and Herzegovina, is a fearless speaker. Since joining T1International’s Global Advocacy Network in July 2021, she has been an invited speaker at the 3rd annual Congress of Diabetologists and Endocrinologists of Bosnia and Herzegovina, serving as a patient representative on a panel of patients and healthcare providers. Read more
Press Release: Human Rights Watch Calls Out Unaffordable Insulin as Human Rights Crisis
12 Apr 2022, 5:21 a.m. in #insulin4all USA, News & Statements by T1International
A report from Human Rights Watch powerfully illustrates the human impact of sky-high insulin prices through the testimony of 18 insulin-dependent people living with diabetes in the United States.
Read more
T1International Statement on HR 6833 and the Affordable Insulin Now Act Vote
31 Mar 2022, 8 p.m. in #insulin4all USA, News & Statements by T1International
On Thursday, March 31st, the US House of Representatives voted to pass a $35 insulin copay cap. The bill now heads to the Senate. While a $35 copay cap on insulin would impact many people, T1International is calling on the Senate to pass a true price cap on insulin for everyone, especially those without insurance. Read more
The Next 100 Years of Insulin
24 Mar 2022, 11:11 p.m. in #insulin4all USA, Global Stories, News & Statements by Ian Devaney
For some, the first 100 years of insulin has been a great, life-affirming success. For others, it has been a failure, where leaders and organizations in power have chosen profits over the lives and welfare of human beings. So how will we shape the next 100 years? Read more
6 Strategies for Ethical Patient Engagement
18 Feb 2022, 10:33 a.m. in #insulin4all USA, News & Statements by T1International
More and more organisations today, from NGOs to global health alliances, are expressing a need for patient engagement and claiming to be patient-informed. As a patient-led organisation, we have noted that patient engagement is often well-intentioned but misguided. While patients might be acknowledged as experts on an event flyer or web page, that expert status does not necessarily mean they are compensated equitably or that their perspectives are valued and/or integrated comparably to other accepted experts, such as physicians or academic researchers. Read more
T1International’s 2021 Top Ten
20 Dec 2021, 5:26 p.m. in News & Statements by T1International
Another year of challenges and outrage, another year of incredible advocacy by our T1International Community! For 2021, we’ve decided to create a Top 10 list of some of our biggest collective achievements. Read more
Greed v. Alec’s Law: Oral Argument at the Eighth Circuit
15 Dec 2021, 2:12 p.m. in #insulin4all USA, News & Statements by Jesus Morales Sanchez
T1International is proud to join T1International’s Minnesota #insulin4all Chapter and patient advocates at the oral argument before the United States Court of Appeals for the Eighth Circuit (Eighth Circuit) in support of upholding Minnesota’s Alec Smith Insulin Affordability Act (Alec’s Law) on December 15, 2021. Read more
T1International Publishes Survey on Type 1 Diabetes, COVID, and Insulin Rationing
18 Oct 2021, 3:15 p.m. in #insulin4all USA, News & Statements by T1International
In September 2021, T1International’s latest out-of-pocket cost survey was published in the Journal of Diabetes Research and Clinical Practice. Conducted every two years, this study is the most comprehensive patient-led out-of-pocket cost survey for people living with type 1 diabetes. Read more
T1International Advocates Win: WHO Adds Long-Acting Insulin Analogues to EML
1 Oct 2021, 2:45 p.m. in News & Statements by T1International
T1International’s global community of people living with and affected by diabetes and their allies celebrates a monumental advocacy win as the World Health Organization announced the addition of long-acting insulin analogues to the Model List of Essential medicines (EML). Read more